ICGI Articles

• No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance

  Published: 24.04.2022

  Cyll K, Löffeler S, Carlsen B, Skogstad K, Plathan ML, Landquist M, Haug ES

  Sci Rep, 12 (1), 6743

  PubMed 35468921

  

• Serglycin Is Involved in TGF-β Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue

  Published: 13.04.2022

  Tellez-Gabriel M, Tekpli X, Reine TM, Hegge B, Nielsen SR, Chen M, Moi L, Normann LS, Busund LR, Calin GA, Mælandsmo GM, Perander M, Theocharis AD, Kolset SO, Knutsen E

  Front Oncol, 12, 868868

  PubMed 35494005

  

• STAMP2 suppresses autophagy in prostate cancer cells by modulating the integrated stress response pathway

  Published: 24.01.2022

  Sikkeland J, Ng MYW, Nenseth HZ, Unal B, Qu S, Jin Y, Simonsen A, Saatcioglu F

  Am J Cancer Res, 12 (1), 327-336

  PubMed 35141021

  

• Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

  Published: 13.06.2021

  Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, Maelandsmo GM, Fodstad Ø, Pulido R, López JI

  Prostate, 81 (12), 838-848

  PubMed 34125445

  

• Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft

  Published: 27.04.2021

  Pandya AD, Iversen TG, Moestue S, Grinde MT, Mørch Ý, Snipstad S, Åslund AKO, Øy GF, Kildal W, Engebråten O, Sandvig K, Skotland T, Mælandsmo GM

  Nanomaterials (Basel), 11 (5)

  PubMed 33924869

  

• Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer

  Published: 03.12.2019

  Ersvær E, Kildal W, Vlatkovic L, Cyll K, Pradhan M, Kleppe A, Hveem TS, Askautrud HA, Novelli M, Wæhre H, Liestøl K, Danielsen HE

  Mod Pathol Dec 4 2019

  PubMed 31801961